Cargando…
Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
BACKGROUND: Reduced time in international normalized ratio therapeutic range (TTR) limits warfarin safety and effectiveness. In patients switched from warfarin to direct oral anticoagulants (DOACs), patient factors associated with low TTR could also increase risk of DOAC nonadherence. We investigate...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075386/ https://www.ncbi.nlm.nih.gov/pubmed/34779243 http://dx.doi.org/10.1161/JAHA.121.020904 |
_version_ | 1784701671819968512 |
---|---|
author | Pundi, Krishna N. Perino, Alexander C. Fan, Jun Schmitt, Susan Kothari, Mitra Szummer, Karolina Askari, Mariam Heidenreich, Paul A. Turakhia, Mintu P. |
author_facet | Pundi, Krishna N. Perino, Alexander C. Fan, Jun Schmitt, Susan Kothari, Mitra Szummer, Karolina Askari, Mariam Heidenreich, Paul A. Turakhia, Mintu P. |
author_sort | Pundi, Krishna N. |
collection | PubMed |
description | BACKGROUND: Reduced time in international normalized ratio therapeutic range (TTR) limits warfarin safety and effectiveness. In patients switched from warfarin to direct oral anticoagulants (DOACs), patient factors associated with low TTR could also increase risk of DOAC nonadherence. We investigated the relationship between warfarin TTR and DOAC adherence in warfarin‐treated patients with atrial fibrillation switched to DOAC. METHODS AND RESULTS: Using data from the Veterans Health Administration, we identified patients with atrial fibrillation switched from warfarin to DOAC (switchers) or treated with warfarin alone (non‐switchers). Logistic regression was used to evaluate association between warfarin TTR and DOAC adherence. We analyzed 128 605 patients (age, 71±9; 1.6% women; CHA(2)DS(2)‐VASc 3.5±1.6); 32 377 switchers and 96 228 non‐switchers. In 8016 switchers with international normalized ratio data to calculate 180‐day TTR before switch, TTR was low (median 0.45; IQR, 0.26–0.64). Patients with TTR <0.5 were more likely to be switched to DOAC (odds ratio [OR],1.68 [95% CI,1.62–1.74], P<0.0001), as were those with TTR <0.6 or TTR <0.7. Proportion of days covered ≥0.8 was achieved by 76% of switchers at 365 days. In low‐TTR individuals, proportion of days covered ≥0.8 was achieved by 70%, 72%, and 73% of switchers with TTR <0.5, 0.6, and 0.7, respectively. After multivariable adjustment, TTR <0.5 decreased odds of achieving 365‐day proportion of days covered ≥0.8 (OR, 0.49; 0.43–0.57, P<0.0001), with similar relationships for TTR <0.6 and TTR <0.7. In non‐switchers with TTR <0.5, long‐term TTR remained low. CONCLUSIONS: In patients with atrial fibrillation switched from warfarin to DOAC, most achieved adequate DOAC adherence despite low pre‐switch TTRs. However, TTR trajectories remained low in non‐switchers. Patients with low warfarin TTR more consistently achieved treatment targets after switching to DOACs, although adherence‐oriented interventions may be beneficial. |
format | Online Article Text |
id | pubmed-9075386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90753862022-05-10 Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin Pundi, Krishna N. Perino, Alexander C. Fan, Jun Schmitt, Susan Kothari, Mitra Szummer, Karolina Askari, Mariam Heidenreich, Paul A. Turakhia, Mintu P. J Am Heart Assoc Original Research BACKGROUND: Reduced time in international normalized ratio therapeutic range (TTR) limits warfarin safety and effectiveness. In patients switched from warfarin to direct oral anticoagulants (DOACs), patient factors associated with low TTR could also increase risk of DOAC nonadherence. We investigated the relationship between warfarin TTR and DOAC adherence in warfarin‐treated patients with atrial fibrillation switched to DOAC. METHODS AND RESULTS: Using data from the Veterans Health Administration, we identified patients with atrial fibrillation switched from warfarin to DOAC (switchers) or treated with warfarin alone (non‐switchers). Logistic regression was used to evaluate association between warfarin TTR and DOAC adherence. We analyzed 128 605 patients (age, 71±9; 1.6% women; CHA(2)DS(2)‐VASc 3.5±1.6); 32 377 switchers and 96 228 non‐switchers. In 8016 switchers with international normalized ratio data to calculate 180‐day TTR before switch, TTR was low (median 0.45; IQR, 0.26–0.64). Patients with TTR <0.5 were more likely to be switched to DOAC (odds ratio [OR],1.68 [95% CI,1.62–1.74], P<0.0001), as were those with TTR <0.6 or TTR <0.7. Proportion of days covered ≥0.8 was achieved by 76% of switchers at 365 days. In low‐TTR individuals, proportion of days covered ≥0.8 was achieved by 70%, 72%, and 73% of switchers with TTR <0.5, 0.6, and 0.7, respectively. After multivariable adjustment, TTR <0.5 decreased odds of achieving 365‐day proportion of days covered ≥0.8 (OR, 0.49; 0.43–0.57, P<0.0001), with similar relationships for TTR <0.6 and TTR <0.7. In non‐switchers with TTR <0.5, long‐term TTR remained low. CONCLUSIONS: In patients with atrial fibrillation switched from warfarin to DOAC, most achieved adequate DOAC adherence despite low pre‐switch TTRs. However, TTR trajectories remained low in non‐switchers. Patients with low warfarin TTR more consistently achieved treatment targets after switching to DOACs, although adherence‐oriented interventions may be beneficial. John Wiley and Sons Inc. 2021-11-15 /pmc/articles/PMC9075386/ /pubmed/34779243 http://dx.doi.org/10.1161/JAHA.121.020904 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Pundi, Krishna N. Perino, Alexander C. Fan, Jun Schmitt, Susan Kothari, Mitra Szummer, Karolina Askari, Mariam Heidenreich, Paul A. Turakhia, Mintu P. Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin |
title | Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin |
title_full | Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin |
title_fullStr | Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin |
title_full_unstemmed | Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin |
title_short | Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin |
title_sort | direct oral anticoagulant adherence of patients with atrial fibrillation transitioned from warfarin |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075386/ https://www.ncbi.nlm.nih.gov/pubmed/34779243 http://dx.doi.org/10.1161/JAHA.121.020904 |
work_keys_str_mv | AT pundikrishnan directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin AT perinoalexanderc directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin AT fanjun directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin AT schmittsusan directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin AT kotharimitra directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin AT szummerkarolina directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin AT askarimariam directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin AT heidenreichpaula directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin AT turakhiamintup directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin |